Hepatitis C Treatment

Oakland County Health Division



Objectives

- Approval process
- Training
- Referral process
- Standing orders
- Unexpected cost
- Sustainability
- Barriers

Approval

MEDICAL DIRECTOR SUPPORT

ADMINISTRATIVE APPROVAL

LIABILITY

PRACTITIONER WILLINGNESS AND AVAILABILITY

Jacqueline Howe, DNP, APRN, FNP-BC, AAHIVS

Nurse Practitioners

Ruby Nzoma, DNP, APRN, FNP-BC

Hepatitis C Resource & Training

- Henry Ford Hospital free consultation line:
 Monday Friday from 8 am 5pm #313-575-0332
- Midwest AIDS Training + Education Center (MATEC) Michigan
- Hepatitis C Training Modules from the University of Wisconsin: https://www.hepatitis.uw.edu
- Dr. Cohn from Wayne State University offers monthly consultation.
- Dr. Cohn's presentation on treating Hepatitis C in Michigan:

https://mediasite.mihealth.org/Mediasite/Play/a 09b36bae91149eb99baa39a001666ab1d

Internal/External referral process

Internal – Clients HCV+ RNA at OCHD

External – MDSS surveillance

Antibody only screening requiring HCV RNA Viral load

Referrals

- Referrals assessed by Hepatitis C Emerging disease RN
- Referrals emailed directly to NP regarding case specifics and MDSS ID
- OCHD referrals distributed based on client demographics
 - Southfield: Jacqueline
 - Pontiac: Ruby
 - **Max capacity/caseload to be determined by individual practitioner
 - **Communication/collaboration with Hep C RN is essential

Simplified Hep C treatment in Adults

Referral to Specialist


- Prior HCV treatment
- HIV or HBV coinfection
- Pregnancy
- Decompensated cirrhosis
- Known/suspected hepatocellular carcinoma
- Prior liver transplantation



- Importance of screening
- One time, routine, opt out HCV testing is recommended for all individuals 18 years and older
- Periodic testing for those with increased risks
- Annual testing recommended for PWID, PLWH, MSM who are taking PrEP

CDC recommended testing







MDHHS Lab

- HCV screening & HCV RNA viral load
- Hepatitis A total antibody
- Hepatitis B surface antibody
- Hepatitis B surface antigen
- HIV 1/2 Ag/Ab combo



genotype \$180-345.00	HCV genotype	•
	0 /1	

 Hepatie 	c Panel	\$3.00
-----------------------------	---------	--------

•	Creatinine	\$1.25

• CBC \$3.00

• PT/INR* \$3.25

• Total Hep B Core Ab \$14.00

• Hep B DNA Quant \$108.36

• Serum HCG \$7.00

Eligibility for simplified treatment without cirrhosis

- Adults with chronic hepatitis C (any genotype) who:
 - Do not have cirrhosis
 - Have not previously received hepatitis C treatment
 - Presumed cirrhosis FIB-4 score > 3.25
 - Mavyret (Glecaprevir/Pibrentasvir)
 x 8 weeks OR
 - Epclusa (Sofosbuvir/velpatasvir) x
 12 weeks

Eligibility for simplified treatment with compensated cirrhosis

- Adults with chronic hepatitis C (any genotype) who have compensated cirrhosis (Child-Pugh A)
- Have not previously received hepatitis C treatment
- Liver biopsy is not required
- CTP > 7 have decompensated cirrhosis and simplified treatment NOT recommended
- Ultrasound of the liver

Goals of treatment

Virologic cure assessed 12 weeks after therapy

Sustained viral response

Limit disease progression

Stop HCV transmission

Monitoring during treatment

Adherence

Side effects

Special precautions for diabetes and those taking warfarin

Monitor hepatic function during therapy if baseline labs are abnormal

Post-Treatment

Hepatic function and HCV RNA 12 weeks after treatment completed

Refer to Specialist if not undetectable

Annual screening if ongoing risk for HCV reinfection is present

Sustainability

Billing

- Minimal billing capabilities
- Medicaid and Blues
- Consideration given to hire biller

340b cost savings

- Private insurance
- 340b pricing vs billable price to insurance = cost savings
- Epclusa \$19,313 for 30 day supply savings shared with MDHHS
- Mavyret \$3502 for 30 day supply savings shared with MDHHS
- Third party SGRX oversight

Budget considerations

- General fund vs Grant funding
- Staffing/Salaries/Benefits
- Laboratory fees
- Medical supplies
- Office supplies
- IT
- Advertising
- Transportation

Overcoming barriers



UNINSURED AND UNDER-INSURED



PATIENT ASSISTANCE PROGRAMS



TRANSPORTATION



CASELOAD



COMMUNITY RESOURCES

Medicare Co-Pay Assistance

- Assess eligibility for Medicaid
- GoodDays: https://www.mygooddays.org/apply
- PAN Foundation: https://www.panfoundation.org/disease-funds/hepatitis-c/ (closed)
- PAF CRP: https://copays.org/funds/hepatitis-c/ (closed)
- Health Well: https://www.healthwellfoundation.org/disease-funds/

QUESTIONS





Jacqueline Howe, DNP, APRN, FNP-BC 248-214-2246

Howej@oakgov.com

Jennifer Erskine, BSN, RN Harm Reduction & HCV Supervisor 248-941-5137

Erskinej@oakgov.com

